Dawson James Securities Strengthens Biotechnology Franchise with Addition of Wall Street Analyst Carol Ann Werther

GlobeNewswire |

BOCA RATON, Fla., (GLOBE NEWSWIRE) -- Dawson James Securities, Inc., is pleased to announce the addition of Carol Ann Werther, Managing Director, Equity Research. Carol has built a 20-year career focused on identifying break through products and science derived from her previous positions in both healthcare clinical research and nutrition education. 

Ms. Werther was most recently Managing Director with H.C. Wainwright & Co., and previously with Summer Street Research Partners, Winslow Management and Adams, Harkness & Hill. Ms. Werther received her MBA Finance from the NYU Stern School of Business and an MS Clinical Nutrition Sciences from the University of Alabama in Birmingham as well as a BS in Nutritional Sciences from Cornell University

Robert D. Keyser, CEO of Dawson James, says, “We are excited to have Carol on board as her deep sector knowledge alongside of her impressive research in therapeutic areas for gene therapy, RNAi and oncology will certainly expand our existing biotechnology expertise led by Robert Wasserman, Director of Research.”

Carol Werther adds, “I am pleased to join the Dawson James team in New York. Their dedication on behalf of small cap growth companies in the Life Science sector was a strong factor in my decision and I look forward to continue to identify compelling ideas in my vertical.”

About Dawson James Securities, Inc.

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

Thomas W. Hands, President thands@dawsonjames.com

Primary Logo

Source: Dawson James Securities, Inc.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Lexaria Bioscience Corp

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within…